EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Humoral SARS-CoV-2 Immune Response in COVID-19 Recovered Vaccinated and Unvaccinated Individuals Related to Post-COVID-Syndrome

Catharina Gerhards iD, Maximilian Kittel iD, Volker Ast, Peter Bugert, Matthias F Froelich iD, Michael Hetjens, Verena Haselmann iD, Michael Neumaier, Margot Thiaucourt

Viruses · 2023

DOI: 10.3390/v15020454 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Catharina Gerhards und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Clinical Chemistry, Medical Faculty Mannheim of the University of Heidelberg, Theodor Kutzer Ufer 1-3, 68167 Mannheim, Germany. Hauptthemen laut MEDLINE: Cell-Free Nucleic Acids, COVID-19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The duration of anti-SARS-CoV-2-antibody detectability up to 12 months was examined in individuals after either single convalescence or convalescence and vaccination. Moreover, variables that might influence an anti-RBD/S1 antibody decline and the existence of a post-COVID-syndrome (PCS) were addressed.

Methods

Forty-nine SARS-CoV-2-qRT-PCR-confirmed participants completed a 12-month examination of anti-SARS-CoV-2-antibody levels and PCS-associated long-term sequelae. Overall, 324 samples were collected. Cell-free DNA (cfDNA) was isolated and quantified from EDTA-plasma. As cfDNA is released into the bloodstream from dying cells, it might provide information on organ damage in the late recovery of COIVD-19. Therefore, we evaluated cfDNA concentrations as a biomarker for a PCS. In the context of antibody dynamics, a random forest-based logistic regression with antibody decline as the target was performed and internally validated.

Results

The mean percentage dynamic related to the maximum measured value was 96 (±38)% for anti-RBD/S1 antibodies and 30 (±26)% for anti-N antibodies. Anti-RBD/S1 antibodies decreased in 37%, whereas anti-SARS-CoV-2-anti-N antibodies decreased in 86% of the subjects. Clinical anti-RBD/S1 antibody decline prediction models, including vascular and other diseases, were cross-validated (highest AUC 0.74). Long-term follow-up revealed no significant reduction in PCS prevalence but an increase in cognitive impairment, with no indication for cfDNA as a marker for a PCS.

Conclusion

Long-term anti-RBD/S1-antibody positivity was confirmed, and clinical parameters associated with declining titers were presented. A fulminant decrease in anti-SARS-CoV-2-anti-N antibodies was observed (mean change to maximum value 30 (±26)%). Anti-RBD/S1 antibody titers of SARS-CoV-2 recovered subjects boosted with a vaccine exceeded the maximum values measured after single infection by 235 ± 382-fold, with no influence on preexisting PCS. PCS long-term prevalence was 38.6%, with an increase in cognitive impairment compromising the quality of life. Quantified cfDNA measured in the early post-COVID-19 phase might not be an effective marker for PCS identification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell-Free Nucleic AcidsCOVID-19HumansAntibodies, ViralConvalescenceImmunity, HumoralQuality of LifeSARS-CoV-2COVID-19 VaccinesPost-Acute COVID-19 Syndrome

Stichwörter der Autor:innen

anti-SARS-CoV-2 antibodiesantibody dynamicsantibody kineticslongitudinal assessmentpost-COVID syndromepost-vaccination boostingserological immune response

Substanzen

Antibodies, ViralCell-Free Nucleic AcidsCOVID-19 Vaccines

Autor:innen und Institutionen

  • Institute for Clinical Chemistry, Medical Faculty Mannheim of the University of Heidelberg, Theodor Kutzer Ufer 1-3, 68167 Mannheim, Germany.
  • Institute of Transfusion Medicine and Immunology, Heidelberg University, 68167 Mannheim, Germany.
  • Medical Faculty Mannheim, European Center for Angioscience (ECAS), Heidelberg University, 68167 Mannheim, Germany.
  • Department of Radiology and Nuclear Medicine, University Medical Center Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany.
  • Department of Biomedical Informatics, Center for Preventive Medicine and Digital Health, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany.

ORCID-Profile: Catharina Gerhards, Maximilian Kittel, Matthias F Froelich, Verena Haselmann

Zitieren

APA

Gerhards, C., Kittel, M., Ast, V., Bugert, P., Froelich, M. F., Hetjens, M., Haselmann, V., Neumaier, M., & Thiaucourt, M. (2023). Humoral SARS-CoV-2 Immune Response in COVID-19 Recovered Vaccinated and Unvaccinated Individuals Related to Post-COVID-Syndrome. Viruses. https://doi.org/10.3390/v15020454

Vancouver

Gerhards C, Kittel M, Ast V, Bugert P, Froelich MF, Hetjens M, et al. Humoral SARS-CoV-2 Immune Response in COVID-19 Recovered Vaccinated and Unvaccinated Individuals Related to Post-COVID-Syndrome. Viruses. 2023. doi:10.3390/v15020454

BibTeX
@article{Gerhards2023,
  author = {Gerhards, Catharina and Kittel, Maximilian and Ast, Volker and Bugert, Peter and Froelich, Matthias F and Hetjens, Michael and Haselmann, Verena and Neumaier, Michael and Thiaucourt, Margot},
  title = {Humoral SARS-CoV-2 Immune Response in COVID-19 Recovered Vaccinated and Unvaccinated Individuals Related to Post-COVID-Syndrome},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15020454}
}
Kostenlos starten →